spacer
home > ebr > winter 2018 > particle acceleration
PUBLICATIONS
European Biopharmaceutical Review

Particle Acceleration

First established more than 200 years ago as a defence against infectious diseases, vaccine development proliferated in the mid-20th century as researchers began to fully exploit the use of inactive and attenuated disease strains. The key to a successful vaccine is to identify and isolate an agent that can be safely administered to the patient to trigger a sufficiently protective immune response, without causing a full-blown illness. For some diseases, a completely inactive strain performs this function, while for others attenuation or modification of an active strain – often by passaging through animal embryos – provides an answer.

More recently, newer vaccine technologies have been adopted to tackle diseases not amenable to these traditional approaches. Today’s researchers routinely deploy subunit and conjugate vaccines – both of which contain only fractions of the pathogen for which they provide protection – and viruslike particles (VLPs). These ‘trick’ the body into an immune response by precisely mimicking the morphology and outer surface of the live virus, but lack the genetic material needed to reproduce, thereby offering the same levels of safety as inactive vaccines. In vivo, such VLPs must be effectively indistinguishable from the active pathogen, so their structure is critical.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Dave Stuart is Medical Research Council Professor of structural biology at the University of Oxford, UK, and joint-head of the division of structural biology at the Department of Clinical Medicine. He was appointed Director of Life Sciences at Diamond Light Source in 2008. Dave’s principal research interests include the structure of viruses and viral proteins, as well as cellular proteins, especially those that interact with viruses.
spacer
Diamond Light Source
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Denny Bros Group continues its support of Packaging Innovations

A world leading print company is preparing to showcase its renowned labelling and printing solutions at next month’s prestigious Packaging Innovations show.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

BioTrinity 2018

23-25 April 2018, Novotel London West in Hammersmith

BioTrinity 2018 is taking place from 23-25 April at the Novotel London West in Hammersmith. Now in its 12th year, BioTrinity remains the leading life sciences biopartnering and investment conference in Europe, and is a must attend event for R&D companies, TTO’s and academia who are looking to meet, collaborate, partner and seek funding from Big Pharma, Investors and Associated Industry companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement